Overview

BE Study of Naftifine HCL

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The current study was randomized, double blind, placebo-controlled, prospective, multicenter, comparative therapeutic equivalence study. The study duration for each patient was 6 weeks: Following were the visit details. V1-Baseline and Randomization Visit (Day 1). V2- End of therapy visit (at the end of week 2 + 2 days). V3- Follow up visit (at the end of week 4 + 2 days). V4 - Test of cure visit ( at the end of week 6 + 4 days).
Phase:
Phase 3
Details
Lead Sponsor:
Genzum Life Sciences
Semler Research Center Pvt. Ltd.
Collaborator:
GenZum Life Sciences LLC
Treatments:
Naftifine